MCID: LMN015
MIFTS: 36

Luminal Breast Carcinoma a

Categories: Cancer diseases

Aliases & Classifications for Luminal Breast Carcinoma a

MalaCards integrated aliases for Luminal Breast Carcinoma a:

Name: Luminal Breast Carcinoma a 12
Breast Tumor Luminal 12 17
Luminal a Breast Carcinoma 12
Luminal Breast Carcinoma 15
Luminal Breast Cancer 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0060548
NCIt 49 C53554
UMLS 71 C3642345

Summaries for Luminal Breast Carcinoma a

Disease Ontology : 12 A breast carcinoma that is characterized by high expression of genes characteristic of luminal epithelial cells, including estrogen receptor (ER), estrogen regulated protein LIV-1, and the transcription factors hepatocyte nuclear factor 3, HNF3A, XBP1, and GATA 3.

MalaCards based summary : Luminal Breast Carcinoma a, also known as breast tumor luminal, is related to adenocarcinoma and estrogen-receptor positive breast cancer. An important gene associated with Luminal Breast Carcinoma a is KDM4C (Lysine Demethylase 4C), and among its related pathways/superpathways are Deubiquitination and Pathways in cancer. The drugs Vitamin D and Calcium, Dietary have been mentioned in the context of this disorder. Affiliated tissues include breast, and related phenotypes are cellular and endocrine/exocrine gland

Related Diseases for Luminal Breast Carcinoma a

Diseases in the Luminal Breast Carcinoma a family:

Luminal Breast Carcinoma B

Diseases related to Luminal Breast Carcinoma a via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 368)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 30.7 TP53 PIK3CA ERBB2 EGFR CDH1
2 estrogen-receptor positive breast cancer 30.3 TP53 PIK3CA PGR GATA3 FOXA1 ESR1
3 breast adenocarcinoma 30.2 TP53 PIK3CA PGR LCOR H2AC18 ESR1
4 breast ductal carcinoma 29.9 TP53 PGR KRT5 ESR1 ERBB2 EGFR
5 leukemia, acute myeloid 29.5 TP53 PIK3CA MIR21 LCOR KDM4C H2AC18
6 ductal carcinoma in situ 29.5 TP53 PIK3CA PGR KRT5 ESR1 ERBB2
7 in situ carcinoma 29.4 TP53 PIK3CA PGR LCOR KRT5 H2AC18
8 breast cancer 29.0 TP53 PIK3CA PGR MIR21 KRT5 H2AC18
9 luminal breast carcinoma b 12.6
10 bartholin's gland adenoid cystic carcinoma 10.7 PGR ESR1
11 chronic tympanitis 10.7 PGR ESR1
12 granulomatous endometritis 10.7 PGR ESR1
13 uterine corpus adenosarcoma 10.7 PGR ESR1
14 vaginal glandular tumor 10.7 PGR ESR1
15 glassy cell carcinoma of the cervix 10.7 PGR ESR1 ERBB2
16 oncocytic breast carcinoma 10.7 PGR ESR1 ERBB2
17 lung leiomyoma 10.7 PGR ESR1
18 vulvar syringoma 10.7 PGR ESR1
19 inverted transitional papilloma 10.7 KRT5 GATA3
20 trigonitis 10.7 PGR ESR1
21 cervical serous adenocarcinoma 10.7 PGR GATA3
22 lipid-rich breast carcinoma 10.6 PGR KRT5 ERBB2
23 hereditary gastric cancer 10.6 CDH1 CD44
24 breast mucinous carcinoma 10.6 PGR KRT5 ERBB2
25 cervical clear cell adenocarcinoma 10.6 PGR ESR1
26 bartholin's gland adenoma 10.6 TP53 PGR ESR1
27 bartholin's gland benign neoplasm 10.6 TP53 PGR ESR1
28 vestibular gland benign neoplasm 10.6 TP53 PGR ESR1
29 scirrhous adenocarcinoma 10.6 PGR ERBB2 CDH1
30 synchronous bilateral breast carcinoma 10.6 PGR BRCA1
31 endometrial squamous cell carcinoma 10.6 TP53 PGR
32 mucoepidermoid esophageal carcinoma 10.6 TP53 KRT5
33 rare head and neck tumor 10.6 TP53 PIK3CA
34 ovarian seromucinous carcinoma 10.6 TP53 PGR ESR1
35 breast squamous cell carcinoma 10.6 KRT5 ERBB2
36 apocrine adenosis of breast 10.6 TP53 PGR ERBB2
37 benign breast adenomyoepithelioma 10.6 KRT5 ESR1 EGFR
38 recurrent respiratory papillomatosis 10.6 ERBB2 EGFR
39 adult type testicular granulosa cell tumor 10.6 PGR ESR1
40 breast adenoid cystic carcinoma 10.6 TP53 PGR ERBB2
41 bizarre leiomyoma 10.6 TP53 PGR ESR1
42 subserous uterine fibroid 10.6 PGR CYP19A1
43 microinvasive cervical squamous cell carcinoma 10.6 KRT5 GATA3
44 breast cystic hypersecretory carcinoma 10.6 KRT5 ERBB2 CDH1
45 linitis plastica 10.6 PGR ERBB2 CDH1
46 mammographic density 10.6 PGR ESR1 CYP19A1
47 gastric papillary adenocarcinoma 10.6 TP53 ERBB2
48 wolffian duct adenocarcinoma 10.6 TP53 GATA3 ESR1
49 biphasic synovial sarcoma 10.6 PGR ESR1 CDH1
50 familiar ovarian carcinoma 10.6 PIK3CA BRCA1

Graphical network of the top 20 diseases related to Luminal Breast Carcinoma a:



Diseases related to Luminal Breast Carcinoma a

Symptoms & Phenotypes for Luminal Breast Carcinoma a

MGI Mouse Phenotypes related to Luminal Breast Carcinoma a:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.35 BRCA1 CD44 CDH1 CYP19A1 EGFR ERBB2
2 endocrine/exocrine gland MP:0005379 10.35 BRCA1 CD44 CDH1 CYP19A1 EGFR ERBB2
3 growth/size/body region MP:0005378 10.34 BRCA1 CD44 CDH1 CYP19A1 EGFR ERBB2
4 cardiovascular system MP:0005385 10.32 BRCA1 CD44 CDH1 CYP19A1 EGFR ERBB2
5 homeostasis/metabolism MP:0005376 10.32 BRCA1 CD44 CDH1 CYP19A1 EGFR ERBB2
6 integument MP:0010771 10.32 BRCA1 CD44 CDH1 CYP19A1 EGFR ERBB2
7 digestive/alimentary MP:0005381 10.3 BRCA1 CD44 CDH1 CYP19A1 EGFR ERBB2
8 mortality/aging MP:0010768 10.28 BRCA1 CD44 CDH1 EGFR ERBB2 ESR1
9 immune system MP:0005387 10.27 BRCA1 CD44 CDH1 CYP19A1 EGFR ESR1
10 embryo MP:0005380 10.2 BRCA1 CDH1 EGFR ERBB2 ESR1 GATA3
11 adipose tissue MP:0005375 10.13 BRCA1 CYP19A1 EGFR ESR1 GATA3 PIK3CA
12 neoplasm MP:0002006 10.11 BRCA1 CD44 CDH1 EGFR ERBB2 ESR1
13 muscle MP:0005369 10.1 BRCA1 CD44 CYP19A1 EGFR ERBB2 ESR1
14 limbs/digits/tail MP:0005371 10.06 BRCA1 CD44 EGFR ERBB2 ESR1 KRT5
15 normal MP:0002873 9.96 BRCA1 CD44 CDH1 CYP19A1 EGFR ERBB2
16 no phenotypic analysis MP:0003012 9.92 CDH1 EGFR ESR1 GATA3 KDM4C PGR
17 reproductive system MP:0005389 9.7 BRCA1 CD44 CDH1 CYP19A1 EGFR ERBB2
18 pigmentation MP:0001186 9.63 BRCA1 CD44 CYP19A1 EGFR GATA3 TP53
19 skeleton MP:0005390 9.32 BRCA1 CD44 CYP19A1 EGFR ERBB2 ESR1

Drugs & Therapeutics for Luminal Breast Carcinoma a

Drugs for Luminal Breast Carcinoma a (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 38)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
2 Calcium, Dietary Phase 4
3 Calciferol Phase 4
4
Calcium Nutraceutical Phase 4 7440-70-2 271
5
Palbociclib Approved, Investigational Phase 3 571190-30-2 5005498 11431660 5330286
6
Fulvestrant Approved, Investigational Phase 3 129453-61-8 104741 17756771
7
Goserelin Approved Phase 3 65807-02-5 5311128 47725
8 Protein Kinase Inhibitors Phase 3
9
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
10
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
11
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
12
Anastrozole Approved, Investigational Phase 2 120511-73-1 2187
13
Exemestane Approved, Investigational Phase 2 107868-30-4 60198
14
Tamoxifen Approved Phase 2 10540-29-1 2733526
15
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
16
Lenvatinib Approved, Investigational Phase 2 417716-92-8
17
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
18
Docetaxel Approved, Investigational Phase 2 114977-28-5 148124
19
Epirubicin Approved Phase 2 56420-45-2 41867
20 Tubulin Modulators Phase 2
21 Antimitotic Agents Phase 2
22 Albumin-Bound Paclitaxel Phase 2
23 Hormone Antagonists Phase 2
24 Estrogen Antagonists Phase 2
25 Estrogen Receptor Antagonists Phase 2
26
Liposomal doxorubicin Phase 2 31703
27 Aromatase Inhibitors Phase 2
28 Estrogens Phase 2
29 Hormones Phase 2
30 Estrogen Receptor Modulators Phase 2
31 taxane Phase 2
32 Immunosuppressive Agents Phase 2
33 Alkylating Agents Phase 2
34 Anti-Bacterial Agents Phase 2
35 Immunologic Factors Phase 2
36 Antirheumatic Agents Phase 2
37 Antibiotics, Antitubercular Phase 2
38 Antineoplastic Agents, Hormonal

Interventional clinical trials:

(show all 12)
# Name Status NCT ID Phase Drugs
1 Hormone Therapy Initiation Immediately After Histological Diagnosis of Breast Cancer, Can it Make Any Difference? Unknown status NCT03111615 Phase 4 Aromatase Inhibitors
2 Multicentre, International Neoadjuvant Randomized Double-blind Trial Comparing Fulvestrant® to a Combination of Fulvestrant® and Palbociclib (CDK 4/6 Inhibitor) in Patients With Operable Luminal Breast Cancer Responding to Fulvestrant® Recruiting NCT03447132 Phase 3 Fulvestrant 500mg;Palbociclib 125mg;Goserelin 3.6 MG;Placebos
3 Phase II, Open-label, Non-randomized Study of Nab-paclitaxel for the Neoadjuvant Treatment of Patients With Stage II and III Luminal Breast Cancer Unknown status NCT01565499 Phase 2 Nab-paclitaxel
4 A Phase II Exploratory, Open-label, Single Arm Study of BYL719 Monotherapy, a Selective Phosphatidylinositol 3-kinase (PI3K) Alpha Inhibitor, in Adult Patients With Advanced Breast Cancer Progressing After First Line Therapy. Unknown status NCT02506556 Phase 2 BYl719
5 Phase Ib Followed by Phase II Study of Pre-operative Treatment With Lenvatinib Combined With Letrozole in Post-menopausal Women With Newly Diagnosed Hormone Receptor Positive Breast Cancer With Measurable Primary Breast Tumor Unknown status NCT02562118 Phase 1, Phase 2 Lenvatinib + Letrozole
6 Tailoring NEOadjuvant Therapy in Hormone Receptor Positive, HER2 Negative, Luminal Breast Cancer. Recruiting NCT03283384 Phase 2 Letrozole;Chemotherapy;Ribociclib plus letrozole
7 Comparative Study for the Degree of Biological Changes After Short-term 2 Weeks and 4 Weeks Preoperative Endocrine Therapy in Luminal Breast Cancer Recruiting NCT04023292 Phase 2 Endocrine therapy;Endocrine therapy
8 Group Sequential Response Adaptive Randomized Clinical Trial of Concomitant Chemotherapy Plus Endocrine Therapy Versus Cyclin-dependent Kinase 4/6 (CDK4/6) Inhibitor Plus Endocrine Therapy for Advanced Hormone Receptor-positive, HER2-negative Breast Cancer. Recruiting NCT03227328 Phase 2 concomitant cyclin-dependent Kinase 4/6 (CDK4/6) inhibitor plus endocrine therapy;chemotherapy plus endocrine therapy (administered either concomitantly or sequentially)
9 A Phase II Window-of-opportunity Study of Single Agent Lenvatinib in Estrogen Receptor Positive Early Stage Breast Cancer Recruiting NCT03168074 Phase 2 lenvatinib
10 Open-label, Randomized, Multicenter, International, Parallel Exploratory Phase II Study, Comparing 3 FEC-3 Docetaxel Chemotherapy to Letrozole + Palbociclib Combination as Neoadjuvant Treatment of Stage II-IIIA PAM 50 ROR-defined Low or Intermediate Risk Luminal Breast Cancer, in Postmenopausal Women Active, not recruiting NCT02400567 Phase 2 Fluorouracile;Epirubicin;Cyclophosphamide;Letrozole;Palbociclib
11 Immediate Breast Reconstruction With Free Greater Omentum for Luminal Breast Cancer Patients Recruiting NCT03370250
12 Adjuvant Endocrine Therapy in Early Stage Breast Cancer: Impact of Drug Adherence/Persistence on Clinical Outcome in Various Breast Cancer Subtypes Active, not recruiting NCT03761420

Search NIH Clinical Center for Luminal Breast Carcinoma a

Genetic Tests for Luminal Breast Carcinoma a

Anatomical Context for Luminal Breast Carcinoma a

MalaCards organs/tissues related to Luminal Breast Carcinoma a:

40
Breast

Publications for Luminal Breast Carcinoma a

Articles related to Luminal Breast Carcinoma a:

# Title Authors PMID Year
1
Nomogram Model of LNR Predicts Survival in Premenopausal Patients with Node-positive Luminal Breast Cancer. 61
28739755 2017

Variations for Luminal Breast Carcinoma a

Expression for Luminal Breast Carcinoma a

Search GEO for disease gene expression data for Luminal Breast Carcinoma a.

Pathways for Luminal Breast Carcinoma a

Pathways related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.75 TP53 H2AC18 GATA3 ESR1 BRCA1
2 12.73 TP53 PIK3CA ESR1 ERBB2 EGFR CDH1
3
Show member pathways
12.61 TP53 PIK3CA ESR1 ERBB2 CDH1
4
Show member pathways
12.51 TP53 PIK3CA ESR1 ERBB2 EGFR CDH1
5
Show member pathways
12.42 TP53 PIK3CA PGR ESR1 ERBB2 EGFR
6
Show member pathways
12.31 PIK3CA ESR1 CD44 BRCA1
7 12.3 TP53 PIK3CA EGFR CD44
8
Show member pathways
12.22 PIK3CA ESR1 ERBB2 EGFR
9
Show member pathways
12.21 TP53 PIK3CA ERBB2 EGFR
10
Show member pathways
12.21 PIK3CA ERBB2 EGFR CDH1
11
Show member pathways
11.93 TP53 PIK3CA ERBB2 EGFR
12 11.92 TP53 ESR1 EGFR CYP19A1 CDH1 BRCA1
13
Show member pathways
11.84 PIK3CA PGR ESR1 ERBB2 EGFR
14 11.81 TP53 PIK3CA MIR21 ESR1 ERBB2 EGFR
15 11.72 TP53 PIK3CA MIR21 MIR19B1 ERBB2 EGFR
16 11.71 TP53 KRT5 GATA3
17 11.66 TP53 PIK3CA ERBB2 BRCA1
18 11.64 TP53 ERBB2 EGFR CDH1
19 11.63 ERBB2 EGFR CDH1
20 11.6 TP53 PIK3CA ERBB2 EGFR
21 11.55 TP53 PIK3CA ERBB2 BRCA1
22 11.46 TP53 CD44 BRCA1
23
Show member pathways
11.41 FOXA1 ESR1 BRCA1
24 11.11 PIK3CA ERBB2 EGFR CDH1
25 10.97 PIK3CA EGFR CDH1
26 10.15 ESR1 CYP19A1

GO Terms for Luminal Breast Carcinoma a

Cellular components related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nuclear chromatin GO:0000790 9.17 TP53 PGR KDM4C H2AC18 GATA3 FOXA1

Biological processes related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.09 TP53 PGR GATA3 FOXA1 ESR1 EGFR
2 positive regulation of transcription, DNA-templated GO:0045893 9.95 TP53 GATA3 ESR1 EGFR CDH1 BRCA1
3 positive regulation of gene expression GO:0010628 9.8 TP53 MIR21 KDM4C GATA3 ERBB2 BRCA1
4 positive regulation of kinase activity GO:0033674 9.73 ERBB2 EGFR CD44
5 chromatin remodeling GO:0006338 9.71 KDM4C GATA3 FOXA1 ESR1
6 response to estrogen GO:0043627 9.7 GATA3 ESR1 BRCA1
7 response to estradiol GO:0032355 9.67 FOXA1 ESR1 EGFR CYP19A1
8 phosphatidylinositol 3-kinase signaling GO:0014065 9.63 PIK3CA GATA3 ERBB2
9 negative regulation of gene expression GO:0010629 9.63 TP53 PGR MIR21 MIR19B1 GATA3 ESR1
10 ERBB2 signaling pathway GO:0038128 9.61 PIK3CA ERBB2 EGFR
11 regulation of transcription by RNA polymerase II GO:0006357 9.61 TP53 LCOR KDM4C GATA3 FOXA1 ESR1
12 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.58 TP53 EGFR
13 positive regulation of RNA polymerase II transcriptional preinitiation complex assembly GO:0045899 9.58 TP53 ESR1
14 negative regulation of production of miRNAs involved in gene silencing by miRNA GO:1903799 9.57 TP53 ESR1
15 positive regulation of histone H3-K9 acetylation GO:2000617 9.54 GATA3 BRCA1
16 negative regulation of ERBB signaling pathway GO:1901185 9.51 ERBB2 EGFR
17 cellular response to indole-3-methanol GO:0071681 9.49 CDH1 BRCA1
18 uterus development GO:0060065 9.43 GATA3 ESR1 CYP19A1
19 positive regulation of protein kinase B signaling GO:0051897 9.1 PIK3CA MIR21 GATA3 ESR1 ERBB2 EGFR

Molecular functions related to Luminal Breast Carcinoma a according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.91 TP53 PGR LCOR GATA3 FOXA1 ESR1
2 zinc ion binding GO:0008270 9.85 TP53 PGR KDM4C GATA3 ESR1 BRCA1
3 chromatin binding GO:0003682 9.72 TP53 KDM4C FOXA1 ESR1 EGFR
4 transcription regulatory region DNA binding GO:0044212 9.71 TP53 GATA3 FOXA1 BRCA1
5 DNA-binding transcription activator activity, RNA polymerase II-specific GO:0001228 9.65 TP53 PGR GATA3 FOXA1 ESR1
6 ATPase binding GO:0051117 9.63 PGR ESR1 EGFR
7 identical protein binding GO:0042802 9.56 TP53 PGR GATA3 ESR1 ERBB2 EGFR
8 nitric-oxide synthase regulator activity GO:0030235 9.16 ESR1 EGFR
9 enzyme binding GO:0019899 9.1 TP53 PGR KDM4C ESR1 EGFR BRCA1

Sources for Luminal Breast Carcinoma a

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....